Alize Pharma closes EUR 3.3 million funding round

07-Jun-2012 - France

Alize Pharma announced that it has completed a funding round of EUR 3.3 million. The funds will allow to take AZP-531, its UAG (UnAcylated Ghrelin) analog, into Phase I clinical trials.

Alize Pharma will carry out the first (Phase I) clinical trial of AZP-531 in healthy volunteers in 2013, which will be followed by Phase Ib and Phase II trials in patients with type II diabetes as well as in patients suffering from the Prader Willi syndrome. Preclinical and clinical data suggest that UAG and its analogs have therapeutic potential in the targeted indications, by reducing acylated ghrelin blood levels, improving glycemic control and insulin sensitivity, and improving additional cardiovascular risk factors.

The company’s main shareholders participated in the funding round, namely Sham, OCTALFA, CEMA Inc. and Thierry Abribat. Since its creation, the company has raised a total of EUR 8.3 million, has created value by reaching significant R&D milestones and has entered into its first strategic partnerships.

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...